Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 30, 2009BloodOpen Access

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

TZThorsten ZenzUniversity of ZurichSHSonja HäbeUniversity of CologneTDTina DenzelUniversity of Cologne

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zenz et al. (2009) studied this question.

synapsesocial.com/papers/6a11ca6eed9c06332dfd37a2https://doi.org/10.1182/blood-2009-05-224071
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia2002 · 789 citations
  2. 2Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway2005 · 98 citations
  3. 3The Prognostic Value of <i>TP53</i> Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness2009 · 304 citations
  4. 4Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E29972007 · 354 citations